Literature DB >> 11215561

Hepatic amyloidosis with light chain deposition disease. A rare association.

M A Casiraghi1, A De Paoli, A Assi, G Palladini, M T Lavazza, A Beretta, G Gualdoni, R Beretta.   

Abstract

Monoclonal immunoglobulin deposition diseases are due to pathological protein deposition in various tissues and organs. Protein deposits may be found in a single tissue or systemically and the organs most frequently involved are kidney, heart, peripheral nerves and the liver. Depending on the pattern of the deposits and the type of immunoglobulin, these diseases are distinguished as primary amyloidosis, light chain deposition disease. Differential diagnosis is made in tissue specimens: microscopically by the identification of positive Congo red staining of the deposits, by immunohistochemical demonstration of proteins reacting with light chain (lambda or kappa) antisera or by recognition of fibrillar structures on electron microscopy. We report an unusual case of light chain deposition disease associated with amyloidosis, where hepatomegaly was the presenting manifestation and liver failure the cause of death, without any kidney involvement.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11215561     DOI: 10.1016/s1590-8658(00)80358-8

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  3 in total

1.  Light chain deposition disease presenting as cholestatic jaundice: a case report.

Authors:  Prasanna N Kumar
Journal:  Oman Med J       Date:  2012-01

2.  A case of fatal intrahepatic cholestasis with primary AL amyloidosis: is early diagnosis possible?

Authors:  Shinichiro Takao; Kosuke Tanaka; Masayuki Miyazaki; Masatake Tanaka; Tomoko Ohashi; Masaki Kato; Kazuhiro Kotoh; Shinichi Aishima; Ryoichi Takayanagi
Journal:  Clin J Gastroenterol       Date:  2013-07-28

3.  Retinal pigment epithelial detachments and tears, and progressive retinal degeneration in light chain deposition disease.

Authors:  Leigh H Spielberg; John R Heckenlively; Anita M Leys
Journal:  Br J Ophthalmol       Date:  2013-02-05       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.